Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars
Executive Summary
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
You may also be interested in...
Finance Watch: Investors Launch New SPACs After Initial Deals
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
4D Pharma Joins The SPAC Trend To Fund Its Keytruda-Boosting Biotherapeutic
The Leeds, UK-based company is looking to the alternative route to the US stock market to fund its live biotherapeutics platform.
Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.